BiondVax Pharmaceuticals - BVXV Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.79
▲ +0.14 (5.28%)

This chart shows the closing price for BVXV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BiondVax Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BVXV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BVXV

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for BiondVax Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.79.

This chart shows the closing price for BVXV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in BiondVax Pharmaceuticals. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2022AegisInitiated CoverageBuy$70.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/9/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2022
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/7/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/6/2023

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
BiondVax Pharmaceuticals logo
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.
Read More

Today's Range

Now: $2.79
Low: $2.53
High: $2.86

50 Day Range

MA: $4.75
Low: $2.59
High: $10.96

52 Week Range

Now: $2.79
Low: $2.37
High: $22.90

Volume

168,393 shs

Average Volume

384,266 shs

Market Capitalization

$3.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.5

Frequently Asked Questions

What sell-side analysts currently cover shares of BiondVax Pharmaceuticals?

The following equities research analysts have issued research reports on BiondVax Pharmaceuticals in the last twelve months: StockNews.com.
View the latest analyst ratings for BVXV.

What is the current price target for BiondVax Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for BiondVax Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for BiondVax Pharmaceuticals in the next year.
View the latest price targets for BVXV.

What is the current consensus analyst rating for BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BVXV.

What other companies compete with BiondVax Pharmaceuticals?

How do I contact BiondVax Pharmaceuticals' investor relations team?

BiondVax Pharmaceuticals' physical mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company's listed phone number is 9723029302529 and its investor relations email address is [email protected] The official website for BiondVax Pharmaceuticals is www.biondvax.com. Learn More about contacing BiondVax Pharmaceuticals investor relations.